Acute Bacterial Skin and Skin Structure Infections Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major acute bacterial skin and skin structure infections markets reached a value of US$ 7.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 14.5 Billion by 2034, exhibiting a growth rate (CAGR) of 6.68% during 2024-2034.
The acute bacterial skin and skin structure infections market has been comprehensively analyzed in IMARC's new report titled "Acute Bacterial Skin and Skin Structure Infections Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acute bacterial skin and skin structure infections (ABSSSI) encompass a spectrum of bacterial infections involving the skin and its underlying structures. These diseases, which can be caused by a range of pathogens, with Staphylococcus aureus and Streptococcus pyogenes being the most common, manifest in various forms, including cellulitis, erysipelas, wound infections, and major abscesses. The symptoms of ABSSSI can vary in severity but typically present as localized redness, warmth, swelling, and pain. Some individuals suffering from the illness may also develop fever, chills, and swollen lymph nodes. Diagnosis of the ailment involves a combination of clinical evaluation and laboratory tests. The healthcare professionals will assess the patient's medical history, physical examination findings, and characteristic symptoms to determine the likely bacterial infection. A wound culture or a sample from the infected site might be obtained to identify the specific bacteria causing the underlying indications. Additionally, imaging studies like ultrasound or MRI may be conducted to assess the extent of tissue involvement.
The escalating incidences of bacterial illnesses in which the pathogens can invade the body through a break in the skin, such as a scratch or a cut, are primarily driving the acute bacterial skin and skin structure infections market. In addition to this, the inflating utilization of advanced medications, like lipoglycopeptides, cephalosporins, oxazolidinones, etc., to address the underlying causative factor of the illness and decrease disease progression is also creating a positive outlook for the market. Moreover, the widespread adoption of wound care therapies, as they aid in preventing infection spread and promoting faster healing, is further propelling the market growth. Apart from this, the rising usage of innovative procedures, including debridement, abscess drainage, and incision and drainage to manage severe cases of ABSSSI, is acting as another significant growth-inducing factor. These techniques, often performed in combination with antibiotic regimens, play a crucial role in reducing the infection's impact and enhancing patient outcomes. Additionally, the emerging popularity of targeted therapies, which are designed to specifically aim at certain molecules or proteins involved in the disease process, thereby ensuring more precise and effective treatment, is expected to drive the acute bacterial skin and skin structure infections market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the acute bacterial skin and skin structure infections market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acute bacterial skin and skin structure infections and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acute bacterial skin and skin structure infections market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the acute bacterial skin and skin structure infections market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the acute bacterial skin and skin structure infections market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current acute bacterial skin and skin structure infections marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the acute bacterial skin and skin structure infections market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the acute bacterial skin and skin structure infections market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the acute bacterial skin and skin structure infections market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of acute bacterial skin and skin structure infections across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of acute bacterial skin and skin structure infections by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of acute bacterial skin and skin structure infections by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with acute bacterial skin and skin structure infections across the seven major markets?
What is the size of the acute bacterial skin and skin structure infections patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of acute bacterial skin and skin structure infections?
What will be the growth rate of patients across the seven major markets?
Acute Bacterial Skin and Skin Structure Infections: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for acute bacterial skin and skin structure infections drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acute bacterial skin and skin structure infections market?
What are the key regulatory events related to the acute bacterial skin and skin structure infections market?
What is the structure of clinical trial landscape by status related to the acute bacterial skin and skin structure infections market?
What is the structure of clinical trial landscape by phase related to the acute bacterial skin and skin structure infections market?
What is the structure of clinical trial landscape by route of administration related to the acute bacterial skin and skin structure infections market?
The acute bacterial skin and skin structure infections market has been comprehensively analyzed in IMARC's new report titled "Acute Bacterial Skin and Skin Structure Infections Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acute bacterial skin and skin structure infections (ABSSSI) encompass a spectrum of bacterial infections involving the skin and its underlying structures. These diseases, which can be caused by a range of pathogens, with Staphylococcus aureus and Streptococcus pyogenes being the most common, manifest in various forms, including cellulitis, erysipelas, wound infections, and major abscesses. The symptoms of ABSSSI can vary in severity but typically present as localized redness, warmth, swelling, and pain. Some individuals suffering from the illness may also develop fever, chills, and swollen lymph nodes. Diagnosis of the ailment involves a combination of clinical evaluation and laboratory tests. The healthcare professionals will assess the patient's medical history, physical examination findings, and characteristic symptoms to determine the likely bacterial infection. A wound culture or a sample from the infected site might be obtained to identify the specific bacteria causing the underlying indications. Additionally, imaging studies like ultrasound or MRI may be conducted to assess the extent of tissue involvement.
The escalating incidences of bacterial illnesses in which the pathogens can invade the body through a break in the skin, such as a scratch or a cut, are primarily driving the acute bacterial skin and skin structure infections market. In addition to this, the inflating utilization of advanced medications, like lipoglycopeptides, cephalosporins, oxazolidinones, etc., to address the underlying causative factor of the illness and decrease disease progression is also creating a positive outlook for the market. Moreover, the widespread adoption of wound care therapies, as they aid in preventing infection spread and promoting faster healing, is further propelling the market growth. Apart from this, the rising usage of innovative procedures, including debridement, abscess drainage, and incision and drainage to manage severe cases of ABSSSI, is acting as another significant growth-inducing factor. These techniques, often performed in combination with antibiotic regimens, play a crucial role in reducing the infection's impact and enhancing patient outcomes. Additionally, the emerging popularity of targeted therapies, which are designed to specifically aim at certain molecules or proteins involved in the disease process, thereby ensuring more precise and effective treatment, is expected to drive the acute bacterial skin and skin structure infections market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the acute bacterial skin and skin structure infections market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acute bacterial skin and skin structure infections and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acute bacterial skin and skin structure infections market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the acute bacterial skin and skin structure infections market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the acute bacterial skin and skin structure infections market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current acute bacterial skin and skin structure infections marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the acute bacterial skin and skin structure infections market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the acute bacterial skin and skin structure infections market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the acute bacterial skin and skin structure infections market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of acute bacterial skin and skin structure infections across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of acute bacterial skin and skin structure infections by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of acute bacterial skin and skin structure infections by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with acute bacterial skin and skin structure infections across the seven major markets?
What is the size of the acute bacterial skin and skin structure infections patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of acute bacterial skin and skin structure infections?
What will be the growth rate of patients across the seven major markets?
Acute Bacterial Skin and Skin Structure Infections: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for acute bacterial skin and skin structure infections drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acute bacterial skin and skin structure infections market?
What are the key regulatory events related to the acute bacterial skin and skin structure infections market?
What is the structure of clinical trial landscape by status related to the acute bacterial skin and skin structure infections market?
What is the structure of clinical trial landscape by phase related to the acute bacterial skin and skin structure infections market?
What is the structure of clinical trial landscape by route of administration related to the acute bacterial skin and skin structure infections market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS - UNMET NEEDS
10 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS - KEY ENDPOINTS OF TREATMENT
11 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS - MARKETED PRODUCTS
11.1 List of Acute Bacterial Skin and Skin Structure Infections Marketed Drugs Across the Top 7 Markets
11.1.1 Orbactiv (Oritavancin)- Melinta Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Nuzyra (Omadacycline) - Paratek Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Dalvance (Dalbavancin) - Allergan
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Sivextro (Tedizolid) - Merck & Co
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS - PIPELINE DRUGS
12.1 List of Acute Bacterial Skin and Skin Structure Infections Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Acute Bacterial Skin and Skin Structure Infections - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Acute Bacterial Skin and Skin Structure Infections - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Acute Bacterial Skin and Skin Structure Infections - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Acute Bacterial Skin and Skin Structure Infections - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Acute Bacterial Skin and Skin Structure Infections - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Acute Bacterial Skin and Skin Structure Infections - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Acute Bacterial Skin and Skin Structure Infections - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Acute Bacterial Skin and Skin Structure Infections - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Acute Bacterial Skin and Skin Structure Infections - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Acute Bacterial Skin and Skin Structure Infections - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Acute Bacterial Skin and Skin Structure Infections - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Acute Bacterial Skin and Skin Structure Infections - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Acute Bacterial Skin and Skin Structure Infections - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Acute Bacterial Skin and Skin Structure Infections - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Acute Bacterial Skin and Skin Structure Infections - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Acute Bacterial Skin and Skin Structure Infections - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Acute Bacterial Skin and Skin Structure Infections - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Acute Bacterial Skin and Skin Structure Infections - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Acute Bacterial Skin and Skin Structure Infections - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Acute Bacterial Skin and Skin Structure Infections - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Acute Bacterial Skin and Skin Structure Infections - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Acute Bacterial Skin and Skin Structure Infections - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Acute Bacterial Skin and Skin Structure Infections - Access and Reimbursement Overview
16 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS - UNMET NEEDS
10 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS - KEY ENDPOINTS OF TREATMENT
11 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS - MARKETED PRODUCTS
11.1 List of Acute Bacterial Skin and Skin Structure Infections Marketed Drugs Across the Top 7 Markets
11.1.1 Orbactiv (Oritavancin)- Melinta Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Nuzyra (Omadacycline) - Paratek Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Dalvance (Dalbavancin) - Allergan
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Sivextro (Tedizolid) - Merck & Co
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS - PIPELINE DRUGS
12.1 List of Acute Bacterial Skin and Skin Structure Infections Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Acute Bacterial Skin and Skin Structure Infections - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Acute Bacterial Skin and Skin Structure Infections - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Acute Bacterial Skin and Skin Structure Infections - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Acute Bacterial Skin and Skin Structure Infections - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Acute Bacterial Skin and Skin Structure Infections - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Acute Bacterial Skin and Skin Structure Infections - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Acute Bacterial Skin and Skin Structure Infections - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Acute Bacterial Skin and Skin Structure Infections - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Acute Bacterial Skin and Skin Structure Infections - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Acute Bacterial Skin and Skin Structure Infections - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Acute Bacterial Skin and Skin Structure Infections - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Acute Bacterial Skin and Skin Structure Infections - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Acute Bacterial Skin and Skin Structure Infections - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Acute Bacterial Skin and Skin Structure Infections - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Acute Bacterial Skin and Skin Structure Infections - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Acute Bacterial Skin and Skin Structure Infections - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Acute Bacterial Skin and Skin Structure Infections - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Acute Bacterial Skin and Skin Structure Infections - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Acute Bacterial Skin and Skin Structure Infections - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Acute Bacterial Skin and Skin Structure Infections - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Acute Bacterial Skin and Skin Structure Infections - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Acute Bacterial Skin and Skin Structure Infections - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Acute Bacterial Skin and Skin Structure Infections - Access and Reimbursement Overview
16 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
